Kate Riddle

Kate is an associate in the Life Sciences group at Goodwin. Kate’s practice focuses on capital markets and corporate matters. Kate represents life sciences companies in a broad range of capital markets transactions including initial public offerings, secondary offerings, PIPEs, and convertible note offerings. In addition to transactional work, Kate counsels clients on Securities Exchange Act reporting, corporate governance, and compliance matters.

Kate is admitted to practice in Pennsylvania only; her application to the New York bar is pending. She is working under the supervision of the partners at Goodwin.

Recent Life Sciences Transactions

• Represented a biotechnology company utilizing a comprehensive cell therapy platform to develop allogeneic cell therapies in its $242.7 million initial public offering*
• Represented a public specialty pharmaceutical company in its $125 million registered notes offering*
• Represented a commercial-stage biotechnology company developing surgical reconstruction products in its $60 million initial public offering*
• Represented a specialty pharmaceutical company focused on therapies for acute care settings in its spin-off from a public contract manufacturing organization and listing on the Nasdaq Capital Market, as well as subsequent public offerings, warrant exchanges and registered direct offerings totaling more than $50 million*
• Represented underwriters in multiple equity offerings and at-the-market offerings for life science issuers*
• Represented various public life sciences companies in connection with at-the-market offerings, follow-on offerings, PIPEs, registered direct offerings and confidentially marketed public offerings*

*Denotes experience prior to joining Goodwin.